Rapid but nondurable response of a BRAF exon 15 double-mutated spindle cell sarcoma to a combination of BRAF and MEK inhibitors
Open Access
- 17 July 2024
- journal article
- case report
- Published by Impact Journals, LLC in Oncotarget
- Vol. 15 (1) , 493-500
Abstract
Https://doi.org/10.18632/oncotarget.28606 Kseniya Sinichenkova, Iliya Sidorov, Nataliya Kriventsova, Dmitriy Konovalov, Ruslan Abasov, Nataliya Usman, Alexander Karachunskiy, Galina Novichkova,...Keywords
This publication has 35 references indexed in Scilit:
- Infantile fibrosarcoma with a novel RAF1 rearrangement: The contemporary challenge of reconciling classic morphology with novel molecular geneticsHuman Pathology: Case Reports, 2020
- BRAF mutation and its inhibitors in sarcoma treatmentCancer Medicine, 2020
- Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trialsThe Lancet Oncology, 2020
- Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trialThe Lancet Oncology, 2017
- Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trialThe Lancet Oncology, 2016
- Doublet BRAF/MEK inhibition versus single-agent BRAF inhibition in the management of BRAF-mutant advanced melanoma, biological rationale and meta-analysis of published dataClinical and Translational Oncology, 2015
- BRAF-mutated clear cell sarcoma is sensitive to vemurafenib treatmentInvestigational New Drugs, 2015
- BRAF inhibitors: the current and the futureCurrent Opinion in Pharmacology, 2015
- Cocoon abdominal: reto diagnóstico y tratamiento. A propósito de un casoCirugía Española, 2015
- Mutations of the BRAF gene in human cancerNature, 2002